Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo (Q39633995)

13 September 2017

title

Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo (English)

1 reference

13 September 2017

1 reference

10

Andrew V Schally

1 reference

13 September 2017

5

Robert Z Orlowski

1 reference

13 September 2017

4

Michael Wang

1 reference

13 September 2017

Jianguo Wen

1

1 reference

13 September 2017

Yongdong Feng

2

1 reference

13 September 2017

Chad C Bjorklund

3

1 reference

13 September 2017

Zheng-Zheng Shi

6

1 reference

13 September 2017

Bing Liao

7

1 reference

13 September 2017

Jacqueline O'Hare

8

1 reference

13 September 2017

Youli Zu

9

1 reference

13 September 2017

Chung-Che Chang

11

1 reference

13 September 2017

publication date

9 November 2010

1 reference

Molecular Cancer Therapeutics

13 September 2017

published in

1 reference

13 September 2017

volume

10

1 reference

13 September 2017

issue

1

1 reference

13 September 2017

page(s)

148-158

1 reference

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

13 September 2017

cites work

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Cancer statistics, 2007

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

GnRH receptor signalling to ERK: kinetics and compartmentalization

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Isolation of the gene and hypothalamic cDNA for the common precursor of gonadotropin-releasing hormone and prolactin release-inhibiting factor in human and rat

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

A new mathematical model for relative quantification in real-time RT-PCR

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Proteasome inhibitors: antitumor effects and beyond

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Effect of cetrorelix acetate on apoptosis and apoptosis regulatory factors in cultured uterine leiomyoma cells

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Expression of gonadotropin-releasing hormone and prothymosin-alpha messenger ribonucleic acid in the ovary

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Gonadotropin-releasing hormone antagonist cetrorelix down-regulates proliferating cell nuclear antigen and epidermal growth factor expression and up-regulates apoptosis in association with enhanced poly(adenosine 5'-diphosphate-ribose) polymerase ex

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

The gene for the neuropeptide gonadotropin-releasing hormone is expressed in the mammary gland of lactating rats.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Gonadotropin-Releasing Hormone Receptors: Characterization, Physiological Regulation, and Relationship to Reproductive Function

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Clinical activity of arsenic trioxide for the treatment of multiple myeloma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Proteasome inhibitor bortezomib for the treatment of multiple myeloma.

1 reference

11 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1158/1535-7163.MCT-10-0829

Identifiers

DOI

10.1158/1535-7163.MCT-10-0829

1 reference

13 September 2017

1 reference